Biotechart

Biotechart
Stealth ModeAn on-chain platform for decentralized science and biotech intellectual property.
About
What does Biotechart do?
Biotechart is a decentralized science (DeSci) platform that enables the tokenization, funding, and trading of biotechnology intellectual property. By leveraging blockchain technology, it connects researchers, institutions, and investors to accelerate scientific discovery and democratize access to biotech assets.
Is Biotechart trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Biotechart is 26 out of 100, based on site security posture and privacy practices.
When was Biotechart founded?
Biotechart was founded in 2026.
What industry does Biotechart operate in?
Biotechart operates in Decentralized Science, Biotech, Web3, Blockchain, Fintech, Tokenized Real-World Assets.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Leading AI agency in Guwahati specializing in biological intelligence, generative AI, and regulatory systems for Asia's underrepresented populations.
Spearmint Resources Inc. is a Canadian mineral exploration company focused on lithium, gold, and antimony projects.
Eccoscience is a startup focused on developing AI-powered solutions for scientific research and discovery.
Feef is a voice-native AI agent that designs personalized fitness, nutrition, supplement, and recovery protocols, integrating them directly into your calendar.
Longevity and metabolic health platform offering personalized insights and interventions.
AI-powered platform for personalized health and longevity.
An entrant is a company tagged Biotech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 1 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.